MPWM Advisory Solutions’s BioMarin Pharmaceuticals BMRN Stock Holding History

MPWM Advisory Solutions’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75	Closed	-$4.24K	–	576
2026 Q1	$4.24K	Hold	75	–	–	﹤0.01%	414
2025 Q4	$4.46K	Hold	75	–	–	﹤0.01%	389
2025 Q3	$4.06K	Hold	75	–	–	﹤0.01%	365
2025 Q2	$4.12K	Hold	75	–	–	﹤0.01%	378
2025 Q1	$5.3K	Hold	75	–	–	﹤0.01%	360
2024 Q4	$4.93K	Buy	+75	New	+$5.02K	﹤0.01%	372

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

MPWM Advisory Solutions's BMRN Position: Q2 2026 in Review

MPWM Advisory Solutions sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 75 shares — an estimated $4.24K sold.

MPWM Advisory Solutions first reported a position in BMRN in Q4 2024 and held it in 6 quarters. The position peaked at $5.3K in Q1 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

MPWM Advisory Solutions reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
MPWM Advisory Solutions sold 75 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $4.24K.
MPWM Advisory Solutions first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 6 quarters.
MPWM Advisory Solutions's BioMarin Pharmaceuticals position peaked at $5.3K in Q1 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on MPWM Advisory Solutions's 13F filing for Q2 2026, filed 13 Aug 2026.